Y-J Wang

List of Publications by Year
in descending order

189 papers	9,020 citations	53751 45 h-index	53190 85 g-index
201 all docs	201 docs citations	201 times ranked	11651 citing authors

#	Article	IF	Citations
1	Peripheral Delivery of Ganglioside GM1 Exacerbates the Pathogenesis of Alzheimerâ€™s Disease in a Mouse Model. Neuroscience Bulletin, 2022, 38, 95-98.	1.5	1
2	Polysaccharide Krestin Prevents Alzheimerâ€™s Disease-type Pathology and Cognitive Deficits by Enhancing Monocyte Amyloid-Î² Processing. Neuroscience Bulletin, 2022, 38, 290-302.	1.5	11
3	Rejuvenating the Immune System: Insights for Anti-Neurodegeneration Strategies. Neuroscience Bulletin, 2022, 38, 107-109.	1.5	3
4	White Matter â€œMattersâ€•in Alzheimerâ€™s Disease. Neuroscience Bulletin, 2022, 38, 323-326.	1.5	3
5	Chronic hypoperfusion due to intracranial large artery stenosis is not associated with cerebral Î²-amyloid deposition and brain atrophy. Chinese Medical Journal, 2022, 135, 591-597.	0.9	1
6	Dynamic changes of CSF sPDGFRÎ²2 during ageing and AD progression and associations with CSF ATN biomarkers. Molecular Neurodegeneration, 2022, 17, 9.	4.4	24
7	The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 1321-1328.	1.2	7
8	Physiological clearance of AÎ² by spleen and splenectomy aggravates Alzheimerâ€type pathogenesis. Aging Cell, 2022, 21, e13533.	3.0	14
9	Inhibiting Î±1â€adrenergic receptor signaling pathway ameliorates <scp>AD</scp>â€type pathologies and behavioral deficits in <scp>APPswe</scp>/<scp>PS1</scp> mouse model. Journal of Neurochemistry, 2022, 161, 293-307.	2.1	7
10	Circulating Naturally Occurring Antibodies to P2RY2 Are Decreased in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 87, 711-719.	1.2	3
11	Biofluid Biomarkers of Alzheimerâ€™s Disease: Progress, Problems, and Perspectives. Neuroscience Bulletin, 2022, 38, 677-691.	1.5	24
12	One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China. JAMA Neurology, 2022, 79, 509.	4.5	133
13	Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimerâ€™s disease. Science Advances, 2022, 8, eabm5667.	4.7	6
14	Effects of Chemotherapy on Neuroinflammation, Neuronal Damage, Neurogenesis, and Behavioral Performance in Bone Marrow Transplantation Recipient Mice. Neurotoxicity Research, 2022, , 1.	1.3	0
15	Combining Multiple Factors to Predict Alzheimerâ€™s Disease. Neuroscience Bulletin, 2022, 38, 969-972.	1.5	1
16	The Association of Serum Neurofilament Light Chain and Acute Ischaemic Stroke Is Influenced by Effective Revascularization. Disease Markers, 2022, 2022, 1-6.	0.6	1
17	Associations of plasma angiostatin and amyloid-Î² and tau levels in Alzheimerâ€™s disease. Translational Psychiatry, 2022, 12, 194.	2.4	2
18	Naturally-Occurring Antibodies Against Bim are Decreased in Alzheimerâ€™s Disease and Attenuate AD-type Pathology in a Mouse Model. Neuroscience Bulletin, 2022, , .	1.5	3

#	Article	IF	Citations
19	The Correlations of Plasma Liver-Type Fatty Acid-Binding Protein with Amyloid-Î² and Tau Levels in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 88, 375-383.	1.2	4
20	Establishment of combined diagnostic models of Alzheimerâ€™s disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS). Translational Psychiatry, 2022, 12, .	2.4	4
21	Gut Microbiota and Alzheimerâ€™s Disease: Pathophysiology and Therapeutic Perspectives. Advances in Alzheimer's Disease, 2022, , .	0.2	0
22	Gut Microbiota Alteration and Its Time Course in a Tauopathy Mouse Model. Advances in Alzheimer's Disease, 2022, , .	0.2	0
23	Blood cell-produced amyloid-Î² induces cerebral Alzheimer-type pathologies and behavioral deficits. Molecular Psychiatry, 2021, 26, 5568-5577.	4.1	32
24	Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study. Brain, 2021, 144, 924-937.	3.7	30
25	Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. Science China Life Sciences, 2021, 64, 926-937.	2.3	12
26	Parabiosis modeling: protocol, application and perspectives. Zoological Research, 2021, 42, 253-261.	0.9	11
27	p75NTR: A Molecule with Multiple Functions in Amyloid-Î² Metabolism and Neurotoxicity. , 2021, , 1-17.		0
28	Association between infectious burden and cerebral microbleeds: a pilot crossâ€sectional study. Annals of Clinical and Translational Neurology, 2021, 8, 395-405.	1.7	6
29	Association of naturally occurring antibodies to Î²-amyloid with cognitive decline and cerebral amyloidosis in Alzheimerâ€™s disease. Science Advances, 2021, 7, .	4.7	26
30	Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimerâ€™s disease. Translational Neurodegeneration, 2021, 10, 6.	3.6	36
31	Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 6074-6082.	4.1	39
32	Comprehensive Management of Daily Living Activities, behavioral and Psychological Symptoms, and Cognitive Function in Patients with Alzheimer's Disease: A Chinese Consensus on the Comprehensive Management of Alzheimer's Disease. Neuroscience Bulletin, 2021, 37, 1025-1038.	1.5	16
33	Should infectious diseases be targeted to prevent dementias?. Lancet Infectious Diseases, The, 2021, 21, 1477-1478.	4.6	1
34	Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. Molecular Neurodegeneration, 2021, 16, 48.	4.4	79
35	Identification of novel drug targets for Alzheimerâ€™s disease by integrating genetics and proteomes from brain and blood. Molecular Psychiatry, 2021, 26, 6065-6073.	4.1	38
36	Gut Microbiota and Alzheimerâ€™s Disease: Pathophysiology and Therapeutic Perspectives. Journal of Alzheimer's Disease, 2021, 83, 963-976.	1.2	4

#	Article	IF	Citations
37	Spicy food consumption is associated with cognition and cerebrospinal fluid biomarkers of Alzheimer disease. Chinese Medical Journal, 2021, 134, 173-177.	0.9	9
38	The genetic risk effects of APOE Îµ4 and novel variants on Chinese familial and sporadic AD.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053544.	0.4	0
39	Early Intervention in Alzheimerâ€™s Disease: How Early is Early Enough?. Neuroscience Bulletin, 2020, 36, 195-197.	1.5	29
40	Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurology, The, 2020, 19, 81-92.	4.9	412
41	Meningeal Lymphatic Vessels: A Drain of the Brain Involved in Neurodegeneration?. Neuroscience Bulletin, 2020, 36, 557-560.	1.5	8
42	The FAM171A2 gene is a key regulator of progranulin expression and modifies the risk of multiple neurodegenerative diseases. Science Advances, 2020, 6, .	4.7	9
43	Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1201-1209.	0.9	258
44	Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimerâ€™s disease-type pathology and cognitive deficits in APP/PS1 mice. Translational Psychiatry, 2020, 10, 230.	2.4	41
45	Cerebrospinal fluid Î±-synuclein predicts neurodegeneration and clinical progression in non-demented elders. Translational Neurodegeneration, 2020, 9, 41.	3.6	7
46	Inflammatory markers in Alzheimer's disease and mild cognitive impairment: A metaâ€analysis and systematic review of 170 studies. Alzheimer's and Dementia, 2020, 16, e041476.	0.4	1
47	Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e042221.	0.4	0
48	Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimerâ€™s disease. Translational Psychiatry, 2020, 10, 423.	2.4	35
49	Peripheral clearance of brain-derived AÎ² in Alzheimer's disease: pathophysiology and therapeutic perspectives. Translational Neurodegeneration, 2020, 9, 16.	3.6	83
50	Selective neuronal vulnerability in Alzheimerâ€™s disease. Ageing Research Reviews, 2020, 62, 101114.	5.0	9
51	Tobacco smoking and the reduced risk of Parkinson disease. Neurology, 2020, 94, 860-861.	1.5	6
52	Association of Polygenic Risk Score with Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease in a Chinese Cohort. Neuroscience Bulletin, 2020, 36, 696-704.	1.5	19
53	LincRNA Plays a Role in the Effect of CYP46A1 Polymorphism in Alzheimerâ€™s Disease â€“ Related Pathology. Frontiers in Aging Neuroscience, 2020, 11, 381.	1.7	7
54	Diagnostic potential of urinary monocyte chemoattractant proteinâ€1 for Alzheimerâ€™s disease and amnestic mild cognitive impairment. European Journal of Neurology, 2020, 27, 1429-1435.	1.7	14

#	Article	IF	Citations
55	The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 625844.	1.4	11
56	Preclinical Study of the Pharmacokinetics of p75ECD-Fc, a Novel Human Recombinant Protein for Treatment of Alzheimerâ€™s Disease, in Sprague Dawley Rats. Current Drug Metabolism, 2020, 21, 235-244.	0.7	7
57	Insulinâ€‘receptor substrate 1 protects against injury inÂendothelial cell models of oxâ€‘LDLâ€‘induced atherosclerosis by inhibiting ER stress/oxidative stressâ€‘mediated apoptosis and activating the Akt/FoxO1 signaling pathway. International Journal of Molecular Medicine, 2020, 46, 1671-1682.	1.8	0
58	Insulinâ€‘receptor substrate 1 protects against injury inï¿½endothelial cell models of oxâ€‘LDLâ€‘induced atherosclerosis by inhibiting ER stress/oxidative stressâ€‘mediated apoptosis and activating the Akt/FoxO1 signaling pathway. International Journal of Molecular Medicine, 2020, 46, 1671-1682.	1.8	3
59	Cellular Trafficking of Amyloid Precursor Protein in Amyloidogenesis Physiological and Pathological Significance. Molecular Neurobiology, 2019, 56, 812-830.	1.9	19
60	Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. Alzheimer's and Dementia, 2019, 15, 1208-1217.	0.4	45
61	Neurotrophin receptor p75 mediates amyloid Î²-induced tau pathology. Neurobiology of Disease, 2019, 132, 104567.	2.1	33
62	DJ-1 is dispensable for human stem cell homeostasis. Protein and Cell, 2019, 10, 846-853.	4.8	13
63	Brain Amyloid-Î² Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 69, 169-178.	1.2	28
64	Evaluation of Peripheral Immune Dysregulation in Alzheimerâ€™s Disease and Vascular Dementia. Journal of Alzheimer's Disease, 2019, 71, 1175-1186.	1.2	12
65	Association of the Polygenic Risk Score with the Incidence Risk of Parkinsonâ€™s Disease and Cerebrospinal Fluid Î±-Synuclein in a Chinese Cohort. Neurotoxicity Research, 2019, 36, 515-522.	1.3	8
66	Gut Microbiota Alteration and Its Time Course in a Tauopathy Mouse Model. Journal of Alzheimer's Disease, 2019, 70, 399-412.	1.2	37
67	Is Alzheimerâ€™s Disease Transmissible in Humans?. Neuroscience Bulletin, 2019, 35, 1113-1115.	1.5	5
68	Plasma Î±â€synuclein levels are increased in patients with obstructive sleep apnea syndrome. Annals of Clinical and Translational Neurology, 2019, 6, 788-794.	1.7	18
69	Neurotrophin Receptor p75 mRNA Level in Peripheral Blood Cells of Patients with Alzheimerâ€™s Disease. Neurotoxicity Research, 2019, 36, 101-107.	1.3	3
70	Genetic Association Between NGFR, ADAM17 Gene Polymorphism, and Parkinsonâ€™s Disease in the Chinese Han Population. Neurotoxicity Research, 2019, 36, 463-471.	1.3	7
71	MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation. Brain, 2019, 142, 176-192.	3.7	44
72	Inflammatory markers in Alzheimerâ€™s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 590-598.	0.9	230

#	Article	IF	Citations
73	Intravenous tirofiban therapy for patients with capsular warning syndrome. Stroke and Vascular Neurology, 2019, 4, 22-27.	1.5	14
74	Knockout of p75 neurotrophin receptor attenuates the hyperphosphorylation of Tau in pR5 mouse model. Aging, 2019, 11, 6762-6791.	1.4	17
75	CYP46A1 and the APOEÎµ4 Allele Polymorphisms Correlate with the Risk of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 8179-8187.	1.9	15
76	The Influence of Abdominal and Ectopic Fat Accumulation on Carotid Intima-Media Thickness: A Chongqing Study. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 1992-1997.	0.7	8
77	The cost of Alzheimer's disease in China and reâ€estimation of costs worldwide. Alzheimer's and Dementia, 2018, 14, 483-491.	0.4	404
78	Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimerâ€™s disease, whereas amyloid deposition does not. Alzheimer's Research and Therapy, 2018, 10, 26.	3.0	42
79	Cysteine-Rich Repeat Domains 2 and 4 are Amyloid-Î² Binding Domains of Neurotrophin Receptor p75NTR and Potential Targets to Block Amyloid-Î² Neurotoxicity. Journal of Alzheimer's Disease, 2018, 63, 139-147.	1.2	9
80	Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimerâ€™s disease and mild cognitive impairment. Molecular Psychiatry, 2018, 23, 767-776.	4.1	48
81	Sortilin inhibits amyloid pathology by regulating non-specific degradation of APP. Experimental Neurology, 2018, 299, 75-85.	2.0	13
82	Blood-derived amyloid-Î² protein induces Alzheimerâ€™s disease pathologies. Molecular Psychiatry, 2018, 23, 1948-1956.	4.1	171
83	p75 neurotrophin receptor interacts with and promotes BACE1 localization in endosomes aggravating amyloidogenesis. Journal of Neurochemistry, 2018, 144, 302-317.	2.1	27
84	The Correlations of Plasma and Cerebrospinal Fluid Amyloid-Beta Levels with Platelet Count in Patients with Alzheimerâ€™s Disease. BioMed Research International, 2018, 2018, 1-7.	0.9	13
85	The paraventricular thalamus is a critical thalamic area for wakefulness. Science, 2018, 362, 429-434.	6.0	225
86	Gut Microbiota is Altered in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 63, 1337-1346.	1.2	538
87	Metabolic syndrome contributes to cognitive impairment in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2018, 55, 68-74.	1.1	15
88	Clinical Research on Alzheimerâ€™s Disease: Progress and Perspectives. Neuroscience Bulletin, 2018, 34, 1111-1118.	1.5	100
89	Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer’s disease model. Drug Design, Development and Therapy, 2018, Volume 12, 2111-2128.	2.0	17
90	Physiological clearance of tau in the periphery and its therapeutic potential for tauopathies. Acta Neuropathologica, 2018, 136, 525-536.	3.9	33

#	Article	IF	Citations
91	The ProNGF/p75NTR pathway induces tau pathology and is a therapeutic target for FTLD-tau. Molecular Psychiatry, 2018, 23, 1813-1824.	4.1	37
92	Associations Between Hepatic Functions and Plasma Amyloid-Beta Levelsâ€"Implications for the Capacity of Liver in Peripheral Amyloid-Beta Clearance. Molecular Neurobiology, 2017, 54, 2338-2344.	1.9	76
93	Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. Acta Neuropathologica, 2017, 134, 207-220.	3.9	90
94	Reduced Cardiovascular Functions inÂPatients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 919-925.	1.2	17
95	Altered peripheral profile of blood cells in Alzheimer disease. Medicine (United States), 2017, 96, e6843.	0.4	46
96	Plasma Amyloid-Beta Levels in Patients with Different Types of Cancer. Neurotoxicity Research, 2017, 31, 283-288.	1.3	40
97	A systemic view of Alzheimer disease â€" insights from amyloid-Î² metabolism beyond the brain. Nature Reviews Neurology, 2017, 13, 612-623.	4.9	581
98	Comorbidity burden of patients with Parkinsonâ€™s disease and Parkinsonism between 2003 and 2012: A multicentre, nationwide, retrospective study in China. Scientific Reports, 2017, 7, 1671.	1.6	33
99	Comorbidity Burden of Dementia: A Hospital-Based Retrospective Study from 2003 to 2012 in Seven Cities in China. Neuroscience Bulletin, 2017, 33, 703-710.	1.5	33
100	Safety and preliminary efficacy of intravenous tirofiban in acute ischemic stroke patient without arterial occlusion on neurovascular imaging studies. Journal of the Neurological Sciences, 2017, 383, 175-179.	0.3	23
101	Cerebrospinal Fluid Amyloid-Î² Levels are Increased in Patients with Insomnia. Journal of Alzheimer's Disease, 2017, 61, 645-651.	1.2	50
102	[O4â€"06â€"02]: PERITONEAL DIALYSIS REDUCES AMYLOIDâ€BETA BURDEN AND ATTENUATES ADâ€TYPE PATHOLOGIES IN THE BRAIN OF AN APP/PS1 MOUSE MODEL. Alzheimer's and Dementia, 2017, 13, P1241.	0.4	0
103	proBDNF Accelerates Brain Amyloid-Î² Deposition and Learning and Memory Impairment in APPswePS1dE9 Transgenic Mice. Journal of Alzheimer's Disease, 2017, 59, 941-949.	1.2	19
104	Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies. Current Alzheimer Research, 2017, 14, 554-561.	0.7	6
105	Nutritional Deficiency in Early Life Facilitates Aging-Associated Cognitive Decline. Current Alzheimer Research, 2017, 14, 841-849.	0.7	35
106	Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 307-316.	0.7	15
107	Intramuscular delivery of p75<scp>NTR</scp> ectodomain by an <scp>AAV</scp> vector attenuates cognitive deficits and Alzheimer's diseaseâ€like pathologies in APP/<scp>PS</scp>1 transgenic mice. Journal of Neurochemistry, 2016, 138, 163-173.	2.1	29
108	The Associations between a Capsaicin-Rich Diet and Blood Amyloid-Î² Levels and Cognitive Function. Journal of Alzheimer's Disease, 2016, 52, 1081-1088.	1.2	36

#	Article	IF	Citations
109	P2â€331: Knockout of P75NTR LigandâEBinding Domain Decreases the Hyperphosphorylation of TAU in P301L Mice Model. Alzheimer's and Dementia, 2016, 12, P769.	0.4	0
110	Association of dementia with death after ischemic stroke: A two-year prospective study. Experimental and Therapeutic Medicine, 2016, 12, 1765-1769.	0.8	7
111	Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients. Stroke, 2016, 47, 2649-2651.	1.0	82
112	Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimerâ€™s disease. Translational Psychiatry, 2016, 6, e907-e907.	2.4	194
113	Demographic and clinical characteristics related to cognitive decline in Alzheimer disease in China. Medicine (United States), 2016, 95, e3727.	0.4	11
114	Sex Dimorphism Profile of Alzheimerâ€™s Disease-Type Pathologies in an APP/PS1 Mouse Model. Neurotoxicity Research, 2016, 29, 256-266.	1.3	89
115	Diagnostic utility of VEGF and soluble CD40L levels in serum of Alzheimer's patients. Clinica Chimica Acta, 2016, 453, 154-159.	0.5	24
116	proBDNF Attenuates Hippocampal Neurogenesis and Induces Learning and Memory Deficits in Aged Mice. Neurotoxicity Research, 2016, 29, 47-53.	1.3	30
117	Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimerâ€™s Drug Discovery. Molecular Neurobiology, 2016, 53, 3565-3575.	1.9	73
118	Common Aging Signature in the Peripheral Blood of Vascular Dementia and Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 3596-3605.	1.9	9
119	Association of Apolipoprotein E (ApoE) Polymorphism with Alzheimer';s Disease in Chinese Population. Current Alzheimer Research, 2016, 13, 912-917.	0.7	15
120	Swedish mutant APP-based BACE1 binding site peptide reduces APP Î²-cleavage and cerebral AÎ² levels in Alzheimerâ€™s mice. Scientific Reports, 2015, 5, 11322.	1.6	25
121	Serum amyloid-beta levels are increased in patients with obstructive sleep apnea syndrome. Scientific Reports, 2015, 5, 13917.	1.6	75
122	An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. Journal of Neuroinflammation, 2015, 12, 153.	3.1	29
123	Nurseâ€led cognitive screening model for older adults in primary care. Geriatrics and Gerontology International, 2015, 15, 721-728.	0.7	11
124	Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of <scp>GSK</scp>3Î² signaling pathway. Journal of Neurochemistry, 2015, 135, 630-637.	2.1	60
125	The association between infectious burden and Parkinson's disease: AÂcase-control study. Parkinsonism and Related Disorders, 2015, 21, 877-881.	1.1	116
126	Association Between Serum Amyloid-Beta and Renal Functions: Implications for Roles of Kidney in Amyloid-Beta Clearance. Molecular Neurobiology, 2015, 52, 115-119.	1.9	55

#	Article	IF	Citations
127	Genetic Association Between APP, ADAM10 Gene Polymorphism, and Sporadic Alzheimerâ€™s Disease in the Chinese Population. Neurotoxicity Research, 2015, 27, 284-291.	1.3	11
128	Associations Between ApoEÎµ4 Carrier Status and Serum BDNF Levelsâ€"New Insights into the Molecular Mechanism of ApoEÎµ4 Actions in Alzheimerâ€™s Disease. Molecular Neurobiology, 2015, 51, 1271-1277.	1.9	26
129	Edaravone alleviates Alzheimerâ€™s disease-type pathologies and cognitive deficits. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5225-5230.	3.3	120
130	Serum AÎ² is Predictive for Short-Term Neurological Deficits After Acute Ischemic Stroke. Neurotoxicity Research, 2015, 27, 292-299.	1.3	18
131	p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimerâ€™s disease. Molecular Psychiatry, 2015, 20, 1301-1310.	4.1	92
132	Parkinson disease with REM sleep behavior disorder. Neurology, 2015, 84, 888-894.	1.5	77
133	Serum Amyloid-Beta Levels are Increased in Patients with Chronic Obstructive Pulmonary Disease. Neurotoxicity Research, 2015, 28, 346-351.	1.3	22
134	Differential levels of p75NTR ectodomain in CSF and blood in patients with Alzheimerâ€™s disease: a novel diagnostic marker. Translational Psychiatry, 2015, 5, e650-e650.	2.4	32
135	Autophagy is involved in oral rAAV/AÎ² vaccine-induced AÎ² clearance in APP/PS1 transgenic mice. Neuroscience Bulletin, 2015, 31, 491-504.	1.5	27
136	Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimerâ€™s disease. Acta Neuropathologica, 2015, 130, 487-499.	3.9	180
137	A study on the association between infectious burden and <scp>A</scp>lzheimer's disease. European Journal of Neurology, 2015, 22, 1519-1525.	1.7	200
138	The association between leukoaraiosis and carotid atherosclerosis: a systematic review and meta-analysis. International Journal of Neuroscience, 2015, 125, 493-500.	0.8	12
139	Clearance of Amyloid-Beta in Alzheimerâ€™s Disease: Shifting the Action Site from Center to Periphery. Molecular Neurobiology, 2015, 51, 1-7.	1.9	79
140	Glucocerebrosidase Gene Mutations Associated with Parkinson's Disease: A Meta-Analysis in a Chinese population. PLoS ONE, 2014, 9, e115747.	1.1	32
141	Specific antibody binding to the APP672â€“699 region shifts APP processing from Î±- to Î²-cleavage. Cell Death and Disease, 2014, 5, e1374-e1374.	2.7	9
142	Effects of (Ã¢Ë†â€™)Epicatechin on the Pathology of APP/PS1 Transgenic Mice. Frontiers in Neurology, 2014, 5, 69.	1.1	32
143	Response to comment: â€˜Association betweenHelicobacter pyloriburden and Alzheimer's diseaseâ€™. European Journal of Neurology, 2014, 21, e101-e101.	1.7	5
144	Mutational analysis in early-onset familial Alzheimer's disease inÂMainland China. Neurobiology of Aging, 2014, 35, 1957.e1-1957.e6.	1.5	48

#	Article	IF	Citations
145	Digital Subtraction Angiography Imaging Characteristics of Patients with Extraâ€“Intracranial Atherosclerosis and Its Relationship to Stroke. Cell Biochemistry and Biophysics, 2014, 69, 599-604.	0.9	9
146	Lessons from immunotherapy for Alzheimer disease. Nature Reviews Neurology, 2014, 10, 188-189.	4.9	71
147	The Association Between Single Nucleotide Polymorphisms of GSK 3Î² Gene and Sporadic Alzheimerâ€™s Disease in a Cohort of Southern Chinese Han Population. Neurotoxicity Research, 2014, 26, 447-453.	1.3	3
148	Identification of a Novel Mutation in the Presenilin 1 Gene in a Chinese Alzheimerâ€™s Disease Family. Neurotoxicity Research, 2014, 26, 211-215.	1.3	7
149	The association of single nucleotide polymorphism of the Fyn gene with sporadic Alzheimer's disease in the Chinese Han population. Neuroscience Letters, 2014, 575, 80-84.	1.0	2
150	General Public Perceptions and Attitudes toward Alzheimer's Disease from Five Cities in China. Journal of Alzheimer's Disease, 2014, 43, 511-518.	1.2	29
151	p75NTR: A Molecule with Multiple Functions in Amyloid-Beta Metabolism and Neurotoxicity. , 2014, , 1925-1944.		0
152	Amyloid beta_{1â€“42} (Aβ₄₂) upâ€regulates the expression of sortilin via the p75<scp>^{NTR}</scp>/RhoA signaling pathway. Journal of Neurochemistry, 2013, 127, 152-162.	2.1	38
153	CYP46A1 T/C polymorphism associated with the APOEÎµ4 allele increases the risk of Alzheimerâ€™s disease. Journal of Neurology, 2013, 260, 1701-1708.	1.8	14
154	The relationship between single nucleotide polymorphisms of the NTRK2 gene and sporadic Alzheimer's disease in the Chinese Han population. Neuroscience Letters, 2013, 550, 55-59.	1.0	20
155	Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies. Drug Discovery Today, 2013, 18, 1212-1220.	3.2	39
156	proNGF inhibits proliferation and oligodendrogenesis of postnatal hippocampal neural stem/progenitor cells through p75NTR in vitro. Stem Cell Research, 2013, 11, 874-887.	0.3	21
157	A Monoclonal Antibody Against the Extracellular Domain of P75 Neurotrophin Receptor. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2013, 32, 55-59.	0.8	4
158	The function of BMP4 during neurogenesis in the adult hippocampus in Alzheimer's disease. Ageing Research Reviews, 2013, 12, 157-164.	5.0	23
159	No association of SORT1 gene polymorphism with sporadic Alzheimerâ€™s disease in the Chinese Han population. NeuroReport, 2013, 24, 464-468.	0.6	13
160	Characteristic Transformation of Blood Transcriptome in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 373-386.	1.2	36
161	The Intracellular Domain of Sortilin Interacts with Amyloid Precursor Protein and Regulates Its Lysosomal and Lipid Raft Trafficking. PLoS ONE, 2013, 8, e63049.	1.1	29
162	Association between the Polymorphism of Estrogen Receptor Ã¡ and Alzheimer's Disease in Chinese Population. Clinical Laboratory, 2013, 59, 741-6.	0.2	6

#	Article	IF	Citations
163	Mycoplasma hyorhinis markedly degrades Î²-amyloid peptides in vitro and ex vivo: a novel biological approach for treating Alzheimer's disease?. American Journal of Translational Research (discontinued), 2013, 5, 634-42.	0.0	1
164	p75NTR is mainly responsible for AÎ² toxicity but not for its internalization: a primary study. Neurological Sciences, 2012, 33, 1043-1050.	0.9	4
165	Immunotherapy for Alzheimer diseaseâ€"the challenge of adverse effects. Nature Reviews Neurology, 2012, 8, 465-469.	4.9	107
166	Autoreactiveâ€AÎ² antibodies promote APP Î²â€secretase processing. Journal of Neurochemistry, 2012, 120, 732-740.	2.1	25
167	Adverse life event and risk of cognitive impairment: a 5â€year prospective longitudinal study in Chongqing, China. European Journal of Neurology, 2012, 19, 631-637.	1.7	10
168	Cerebral ischemia aggravates cognitive impairment in a rat model of Alzheimer's disease. Life Sciences, 2011, 89, 86-92.	2.0	58
169	Association between Bone Mineral Density and the Risk of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 101-108.	1.2	80
170	Roles of p75NTR in the pathogenesis of Alzheimer's disease: A novel therapeutic target. Biochemical Pharmacology, 2011, 82, 1500-1509.	2.0	55
171	The p75NTR extracellular domain. Prion, 2011, 5, 161-163.	0.9	21
172	p75NTR Regulates AÎ² Deposition by Increasing AÎ² Production But Inhibiting AÎ² Aggregation with Its Extracellular Domain. Journal of Neuroscience, 2011, 31, 2292-2304.	1.7	84
173	PPARÂ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells. Cardiovascular Research, 2011, 92, 484-493.	1.8	48
174	Modified Immunotherapies Against Alzheimer's Disease: Toward Safer and Effective Amyloid-Î² Clearance. Journal of Alzheimer's Disease, 2010, 21, 1065-1075.	1.2	20
175	Vascular Risk Aggravates the Progression of Alzheimer's Disease in a Chinese Cohort. Journal of Alzheimer's Disease, 2010, 20, 491-500.	1.2	24
176	Effects of proNGF on Neuronal Viability, Neurite Growth and Amyloid-beta Metabolism. Neurotoxicity Research, 2010, 17, 257-267.	1.3	30
177	Nicotine exacerbates tau phosphorylation and cognitive impairment induced by amyloid-beta 25â€"35 in rats. European Journal of Pharmacology, 2010, 637, 83-88.	1.7	27
178	ProBDNF inhibits infiltration of ED1+ macrophages after spinal cord injury. Brain, Behavior, and Immunity, 2010, 24, 585-597.	2.0	51
179	Intramuscular delivery of a single chain antibody gene prevents brain AÎ² deposition and cognitive impairment in a mouse model of Alzheimerâ€™s disease. Brain, Behavior, and Immunity, 2010, 24, 1281-1293.	2.0	35
180	Role of Hypertension in Aggravating A<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î²</mml:mi></mml:math> Neuropathology of AD Type and Tau-Mediated Motor Impairment. Cardiovascular Psychiatry and Neurology, 2009, 2009, 1-9.	0.8	46

#	Article	IF	Citations
181	Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer's disease. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 661, 25-34.	0.4	75
182	Consumption of Grape Seed Extract Prevents Amyloid-Î² Deposition and Attenuates Inflammation in Brain of an Alzheimerâ€™s Disease Mouse. Neurotoxicity Research, 2009, 15, 3-14.	1.3	192
183	Intramuscular delivery of a single chain antibody gene reduces brain AÎ² burden in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2009, 30, 364-376.	1.5	49
184	Differential effects of proâ€BDNF on sensory neurons after sciatic nerve transection in neonatal rats. European Journal of Neuroscience, 2008, 27, 2380-2390.	1.2	49
185	Grape-Derived Polyphenolics Prevent AÂ Oligomerization and Attenuate Cognitive Deterioration in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2008, 28, 6388-6392.	1.7	339
186	Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discovery Today, 2006, 11, 931-938.	3.2	173
187	Immune tolerance induced by gamma-ray irradiation. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2003, 15, 121-123.	0.7	0
188	Study of the relationship between cigarette smoking, alcohol drinking and cognitive impairment among elderly people in China. Age and Ageing, 2003, 32, 205-210.	0.7	97
189	The association of serum uric acid with cognitive impairment and ATN biomarkers. Frontiers in Aging Neuroscience, 0, 14, .	1.7	3